Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 6Crohn Disease 4Colitis, Ulcerative 4Colitis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Inflammatory Bowel Diseases 3Arthritis, Rheumatoid 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1Lymphoma 1Kidney Transplantation 1Hypertension 1

Interventions

Cyclophosphamide 64Tacrolimus 55Methotrexate 46Mycophenolic Acid 39Cyclosporine 37fludarabine phosphate 35Busulfan 35Antilymphocyte Serum 32fludarabine 29Sirolimus 26Melphalan 23Peripheral Blood Stem Cell Transplantation 22Radiotherapy 21Methylprednisolone 21Whole-Body Irradiation 19Filgrastim 17thymoglobulin 14Thiotepa 11Stem Cell Transplantation 10Rituximab 10ruxolitinib 9Granulocyte Colony-Stimulating Factor 9Prednisone 7Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Alemtuzumab 7Pentostatin 6Cytarabine 6Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Graft vs Host Disease × Infliximab × Clear all
NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT00228839 2009-06-30

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

Emory University

Phase 1 Completed

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡